Clinical Trials Browser

NCT05633602 2026-04-17

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Phase 3 Active not recruiting

838 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

855 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT02392429 2026-04-13

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2 Active not recruiting

87 enrolled 15 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03939481 2026-04-13

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

Active not recruiting

1,336 enrolled

GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms

NCT04528680 2026-04-13

SC9/ABX

Phase 1/2 Active not recruiting

57 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT05710328 2026-04-03

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Phase 2 Active not recruiting

235 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT06504615 2026-04-03

METAGIO

Active not recruiting

208 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Adenocarcinoma

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Phase 2 Active not recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05763199 2026-03-12

Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy

Phase 2 Active not recruiting

20 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01928589 2026-03-06

Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer

Phase NA Active not recruiting

81 enrolled

Breast

Breast Neoplasms

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

410 enrolled

Other solid neoplasm

Select Advanced Solid Tumors

NCT04928807 2026-02-27

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

Phase 3 Active not recruiting

231 enrolled

Gastrointestinal

Rectal Neoplasms

NCT03774732 2026-02-25

NIRVANA-LUNG

Phase 3 Active not recruiting

327 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03943173 2026-02-25

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Phase EARLY_PHASE1 Active not recruiting

15 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07429318 2026-02-24

GC/GEJC

Active not recruiting

300 enrolled

Gastrointestinal

Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Phase 1/2 Active not recruiting

194 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05421897 2026-01-29

RAPID

Phase 1 Active not recruiting

11 enrolled

CNS

Neoplasms, Neuroblastoma

NCT03210103 2026-01-28

ORATOR2

Phase NA Active not recruiting

61 enrolled

Head & Neck

Head and Neck Neoplasms, Oropharyngeal Neoplasms